Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Press Release

iSchemaView Introduces New Mobile and Notification Platform Features Across Its Family of Rapid Products

Messaging, Notification and Rapid Mobile App Enhancements to the RAPID Intelligent Services Platform Further Elevate the De Facto Standard Imaging Platform for Stroke Care Menlo Park, Calif. and Danvers, Mass. — January 31, 2019 — iSchemaView, the worldwide leader in advanced imaging for stroke, today announced significant upgrades to the RAPID APP as well as other messaging and notification capabilities. In its latest release, the world’s most powerful and feature-rich neuroimaging software, RAPID, now includes additional customization of notifications for hospitals and physicians. It also incorporates support to customize the delivery of critical Personal Health Information (PHI) and of RAPID’s latest indication for thrombectomy. Developed by leading stroke experts, the RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, text, the RAPID APP or corporate partner workflow systems. “The latest updates to RAPID’s powerful mobile capabilities provide critical convenience and functionality for all of our users,” said Anil Singhal, MD, iSchemaView SVP Worldwide Operations. “The enhanced RAPID Intelligent Services Platform enables stroke specialists and their teams to communicate with a speed and accuracy that can improve outcomes for stroke patients in what is always a time-sensitive environment.” New mobile enhancements to the RAPID Intelligent Services Platform, include: Custom notifications for any RAPID module — RAPID CTA, RAPID ASPECTS, RAPID CTP and RAPID MRI Delivery of the right information to the right people at the right time with notifications customized by hospital, physician or by case New options for PHI, offering customized PHI content limits to accommodate local regulations, hospital policies or physician preferences Notification support of RAPID’s additional FDA clearance regarding thrombectomy — the new clearance notes that RAPID CT-Perfusion and RAPID MR-Perfusion can be used by physicians to aid in the selection of acute stroke patients with known occlusion of the internal carotid artery or proximal middle cerebral artery for a clot removal procedure; RAPID is the only imaging platform approved for selecting stroke patients for clot removal Updated release of the RAPID APP on both Apple iOS and Android platforms The latest release of RAPID empowers hospitals and stroke centers to set custom email, text or in-app notifications for physicians and clinical team members based on clinical thresholds across modules. RAPID also integrates with third-party communication and messaging applications designed for the hospital environment. In addition, users of the RAPID APP can view raw Non-Contrast CT images and CTA source data. These enhancements to the RAPID Intelligent Services Platform improve the speed with which time-critical RAPID brain scans and results reach members of an acute stroke care team. This accelerates key diagnostic decision making for the patient and facilitates the care team’s communication.
featured-image

Press Release

iSchemaView and NeuroLogica Team Up to Mobilize Stroke Care Worldwide

Best-in-Class Stroke Imaging Platform and Leading Mobile CT Scanner Integrate to Accelerate Mobile Stroke Evaluation and Treatment Menlo Park, Calif. and Danvers, Mass. — January 22, 2019 — iSchemaView, the worldwide leader in advanced imaging for stroke, and NeuroLogica, a subsidiary of Samsung Electronics Co., Ltd. and leader in medical imaging technology, today announced a partnership to integrate iSchemaView’s RAPID™ cerebrovascular imaging platform with NeuroLogica’s portable CereTom® computed tomography (CT) scanners for use in Mobile Stroke Units (MSUs) and Intensive Care Units (ICUs) across the globe. “We are thrilled to partner with NeuroLogica and its leading mobile CT system at the forefront of MSU programs across the country,” said Anil Singhal, MD, SVP, Worldwide Operations at iSchemaView. “In addition, we are excited that our partnership allows the option of RAPID advanced imaging on CereToms in more than 500 ICUs worldwide.” The CereTom is an 8-slice mobile CT scanner that delivers high-quality, non-contrast CT, CT angiography and CT perfusion scans in a variety of patient locations. RAPID is the most advanced, fully automated and only clinically proven stroke imaging platform available. It provides intuitive and easily interpretable real-time views of brain perfusion and allows clear visualization of the cerebral arteries. In conjunction, their speed, easeof-use and fast results make CereTom and RAPID indispensable tools for MSUs and ICUs, helping medical teams make life-saving triage, diagnostic and treatment decisions. RAPID is the only brain imaging platform that is FDA-cleared for selecting stroke patients for clot removal, also known as thrombectomy. “By assessing patients in MSUs equipped with both CereTom and RAPID technologies, we will be able to swiftly identify the right course of action — on site treatment with clotbusting agents or appropriate hospital transport for thrombectomy — thereby optimizing outcomes and quality of life,” said David Webster, Chief Operating Officer at NeuroLogica. Developed by leading stroke experts, RAPID combines unmatched expert features, proprietary algorithms and machine learning to deliver the best-in-class advanced stroke imaging and analysis. RAPID provides hypoperfusion, cerebral blood volume indexes, custom notifications and thresholding — including golden-hour thresholds. And RAPID is the only system that delivers results to mobile devices in less than 90 seconds, either by mobile app or email. “This is a new frontier in stroke care. We are bringing state-of-the-art technology directly to patients, no matter where they are. This allows us to make fast, accurate assessments of their clinical status and provide effective treatment directly in the MSU or transport the patient to the appropriate hospital for expedited clot removal,” said Dr. James Grotta, Director of the Mobile Stroke Unit Consortium and Director of Stroke Research for the Clinical Institute for Research and Innovation at the Memorial Herman–Texas Medical Center.
featured-image

Press Release

Rapid Imaging Platform Powers Mobile Stroke Units

The Leading Imaging Software for Ischemic Stroke is Now Compatible with All CT Scanners for Mobile Stroke Units Menlo Park, Calif. —November 29, 2018 — iSchemaView, the worldwide leader in advanced imaging for stroke, today announced that the RAPID imaging platform is now fully compatible with the imaging hardware in use in Mobile Stroke Units (MSU). RAPID is the imaging solution of choice for the mobile stroke unit of Houston’s Memorial Hermann Healthcare System — the very first MSU in the nation. The Mobile Stroke Unit is a specialized ambulance for prehospital stroke treatment, which provides the diagnostic tools and stroke expertise to enable therapeutic treatment at the site of the emergency. When treated in a Mobile Stroke Unit, patients can be evaluated, imaged and treated before they are transported via ambulance to the emergency department, and data suggests that prehospital treatment can save a critical hour — almost doubling the odds of a patient being discharged directly to home after their stroke. It is expected that patients treated on the MSU will have fewer long-term disabilities, providing them with a better quality of life and potentially reducing overall healthcare costs. “This novel model for delivering acute stroke treatment is advancing stroke care in Houston and has the potential for broad impact across the nation,” said Dr. James Grotta, Director of Stroke Research for the Clinical Institute for Research and Innovation at the Memorial Hermann–Texas Medical Center and Director of the Mobile Stroke Unit Consortium. “iSchemaView’s RAPID is an important tool to speed our ability to properly triage patients.” Since 2014, the number of Mobile Stroke Units in the United States has grown to more than 17, with three additional units soon to become operational. RAPID is compatible with all MSUs, regardless of hardware solution. “Our research at UCLA shows that in a typical stoke where there is a large vessel occlusion, two million brain cells die for every minute that goes by without treatment, underscoring just how critical a rapid response to stroke is,” said Dr. May Nour, Medical Director of the UCLA Arline and Henry Gluck Stroke Rescue Program. “We are looking forward to bringing RAPID into our Mobile Stroke Unit — the first of its kind in the Western U.S. This added level of imaging analysis will lead to more efficient diagnosis and triage of patients requiring routing to advanced stroke centers directly from the field.” Developed by leading stroke experts, RAPID combines unmatched expert feature extraction, proprietary algorithms and machine learning to deliver the best-in-class platform, which includes tools for CT perfusion, MR diffusion and perfusion, CT angiography and CT ASPECT scoring. RAPID modules feature custom notifications, custom thresholding, hypoperfusion and cerebral blood volume indexes and golden hour thresholds. And RAPID is the only system which delivers results to mobile devices in less than 90 seconds, whether by email or hospital PACS.
featured-image

Press Release

iSchemaView Rapid Integrates with Join, Allms Medical Communications Platform

RAPID’s Advanced Imaging Results, the Standard for Over 700 Stroke Centers, Now Also Available via Join’s Medical Communications App. Menlo Park, Calif. — November 14, 2018 — iSchemaView, the worldwide leader in advanced imaging for stroke, today announced that the RAPID platform is now compatible with Join, a medical communication app developed by Allm, a multinational developer of mobile communications platforms for the healthcare industry. The integration of RAPID imaging results into the Join platform allows for time-critical brain scans to be quickly and securely shared among the members of the acute stroke care team, to accelerate key diagnostic decision making for the patient and facilitate the care team’s communication. RAPID is the de facto standard for the automated analysis of brain images used for the diagnosis and treatment of stroke, including CT angiography, CT perfusion, MR diffusion and perfusion and CT ASPECT scoring, which can now be easily accessed through the Join app. This integration enables another channel for streamlined connections with physicians, EMS and healthcare imaging communication systems such as PACS, allowing medical professionals to share clinical information broadly and quickly. “As a long-term RAPID customer, we are thrilled with the accessibility of RAPID cases via the Join platform.” said Dr. James Conners, Associate Professor of Neurology, Rush University Medical Center. “Our personal user experience with the combined platform has been nothing less than positive. The integration allows for swift and seamless communication with the stroke care stakeholders from the ambulance to the angiosuite.” Developed by leading stroke experts, RAPID combines unmatched expert feature extraction and other proprietary machine learning algorithms to deliver the best-in-class platform that has quickly become the standard in three-quarters of U.S. comprehensive stroke centers. “By integrating with Join, we are utilizing another critical mobile channel to bring RAPID’s unmatched imaging results to medical professionals around the globe,” said Anil Singhal, MD, iSchemaView SVP Worldwide Operations. “Together we are facilitating communication about critical patient information, in context, right from mobile devices. We are also excited to have Allm join our mission to successfully diagnose and treat more stroke patients than ever before.” “Allm’s goal is to create next-generation mobile technologies and communications platforms for the healthcare industry that truly benefit medical professionals and improve patient care,” said Harry Reddy, President of Allm North America, and GM of Global Strategy Division of Allm Group. “Creating integration between our Join app and RAPID’s imaging helps advance Allm’s goal. We look forward to expanding RAPID’s reach and the integration with the Join app worldwide.” "Diagnosis of acute stroke is a high pressure, time-sensitive situation,” said Dr. Marc Ribo of the University of Barcelona. “The combination of the RAPID and Join platforms is a powerful tool to enable our team to confidently get the stroke patient to the right clinical treatment in this life-threatening environment.”
featured-image

Press Release

iSchemaView's Rapid Adopted by More Than 700 Stroke Centers Over 100 Percent Growth This Year

More Than 2,000 Cases Weekly on RAPID’s Advanced Imaging Platform, the Imaging Standard for Stroke Centers Redwood City, Calif. – October 29, 2018 — Today, on World Stroke Day, iSchemaView, the worldwide leader in advanced imaging for stroke, announced that adoption of its RAPID advanced imaging platform has grown more than 100 percent year-to-date. Over 700 stroke centers around the world have now contracted to use the RAPID platform commercially, and over 300 sites are installing RAPID for clinical research, including multinational trials. “On a day dedicated to stroke awareness, we are proud to play a growing role in helping stroke patients globally,” said Don Listwin, CEO of iSchemaView. “With stroke centers now delivering over 100,000 RAPID cases a year, dramatically more patients are receiving treatment than ever before.” RAPID has quickly become the ubiquitous standard in the analysis of brain images using automated tools for CT ASPECTS, CT angiography, CT perfusion and MR diffusion and perfusion. Developed by leading stroke experts, RAPID combines unmatched expert feature extraction, proprietary algorithms and machine learning to deliver the best-in-class platform, one that has quickly become the standard in three quarters of U.S. comprehensive stroke centers. “This is an amazing moment in stroke medicine, and with the backdrop of World Stroke Day, it is the ideal time to celebrate the landmark research that has recently opened new treatment windows for so many more patients,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of iSchemaView. “We are incredibly gratified that the RAPID platform, built on clinical data and deep stroke expertise, is helping researchers drive this transformation in the treatment of stroke.” RAPID, the worldwide imaging platform of choice for stroke research, was chosen as the imaging solution for patient selection in five groundbreaking clinical trials. These include SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and, most recently, EXTEND. In addition to transforming selection for thrombectomy procedures, the positive results of the EXTEND trial that were recently presented at the World Stroke Congress, demonstrate that RAPID may now allow primary stroke centers to potentially provide effective treatment for patients who present beyond the traditional time window for intravenous tPA therapy. “I would like to congratulate the EXTEND investigators for this landmark achievement,” continued Dr. Albers. “For the last two decades, numerous investigators have attempted to expand the window for intravenous tPA therapy. The results of the EXTEND study will dramatically increase the number of patients who can benefit from intravenous thrombolysis.” Under IRB approval, the RAPID platform was also used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies helped change the American Heart Association and American Stroke Association’s stroke guidelines to include CT perfusion and MR perfusion. The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well.
featured-image

Press Release

iSchemaView's Rapid Approved for Use in Canada

Patients Suffering Ischemic Stroke in Canada Now Have Access to the Only Clinically Validated, Next-Generation Imaging Platform for Assessing Treatment Redwood City, Calif. – August 16, 2018 – iSchemaView, the leader in cerebrovascular imaging analysis, today announced it has received final approval for the use of the RAPID platform in Canada. The RAPID platform is designed to provide physicians with fast, fully automated, elegant and easy-to-interpret imaging that facilitates clinical decision-making around cerebrovascular disease, such as stroke. Canadian approval comes after iSchemaView’s quality system was certified through the Medical Device Single Audit Program (MDSAP) — a global approach to auditing and monitoring the manufacturing of medical devices, in an effort to improve safety and oversight on an international scale. iSchemaView’s RAPID platform was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies helped change the American Heart Association’s and Canadian Heart and Stroke Foundation’s stroke guidelines to include CT perfusion and MR perfusion. The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well. “Our research use of RAPID has shown that its speed and accuracy are very helpful in the management of patients with acute stroke,” said Dr. Frank Silver, Medical Director, Toronto West Stroke Network; Medical Director of the Ontario Telestroke Program and Professor of Neurology at the University of Toronto. “RAPID plays an important role in selecting which patients should be urgently transferred to regional stroke centers for endovascular therapy.” RAPID technology assists physicians in the analysis of brain images using automated tools for CT ASPECTS, CT angiography, CT perfusion and MR diffusion and perfusion for more than 85,000 stroke cases per year. RAPID is also currently deployed in six multi-center clinical trials globally — adding 200 hospitals to RAPID’s global reach. The RAPID neuroimaging platform creates high-quality images from non-contrast CT, CT angiography, CT perfusion and MRI diffusion and perfusion studies. The software provides an intuitive and easily interpretable real-time view of brain perfusion, allowing physicians to determine lesion volumes for a wide variety of different thresholds. Also approved for use in Canada is RAPID ASPECTS, a validated solution that assists clinicians in assessing early signs of brain ischemia in stroke. RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. “With approval for RAPID in Canada, we will be able to greatly expand the number of health care facilities that are able to assess stroke patients with the only clinically validated next-generation imaging technology,” said Don Listwin, CEO of iSchemaView. “Over 575 stroke centers in 22 countries around the world have now committed to using the RAPID platform, and we look to increasing that number substantially by the end of the year.” For more information about working with RAPID in Canada, contact Cynthia Yang at +1 (949) 836-7402 or at yang@irapid.com .
featured-image

Press Release

iSchemaView Rapid Technology Now Installed in More Than 500 Stroke Centers Up 48% Since April

Explosive Growth of the De Facto Standard for Advanced Cerebrovascular Imaging Redwood City, Calif. – August 14, 2018 — iSchemaView, the leader in cerebrovascular imaging analysis, today announced accelerated adoption of the RAPID advanced imaging platform. Over 575 stroke centers in 22 countries around the world have now committed to using the RAPID platform, with 520 currently installed. RAPID technology assists physicians in the analysis of brain images using automated tools for CT ASPECTS, CT angiography, CT perfusion, MR diffusion and perfusion for more than 85,000 stroke cases per year. RAPID is also currently deployed in six multi-center clinical trials globally — adding 200 hospitals to RAPID’s global reach. “Stroke centers want the very best technology to improve patient outcomes, and RAPID’s reputation as the platform of choice for stroke research has accelerated the pace of our growth tremendously,” said Don Listwin, CEO of iSchemaView. “The fast growth of the RAPID platform — the only next-generation imaging platform validated in multiple clinical trials — means a substantial increase in the number of addressable patients who have suffered ischemic stroke.” Under IRB approval, iSchemaView’s RAPID platform was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies helped change the American Heart Association and American Stroke Association’s stroke guidelines to include CT perfusion and MR perfusion. The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well. “In addition to individual stroke centers, iSchemaView’s RAPID platform has recently been adopted by several large hospital systems, including 17 hospitals of Baylor Scott & White Health,” said Anil Singhal, MD, Senior Vice President for iSchemaView. “By deploying RAPID through large hospital systems in a hub and spoke model, more patients will be able to get the right treatment at the most appropriate facility, vastly improving patient care and at the same time increasing hospital efficiency.” The RAPID neuroimaging platform creates high-quality images from non-contrast CT, CT angiography, CT perfusion and MRI diffusion and perfusion studies. The software provides an intuitive and easily interpretable real-time view of brain perfusion, allowing physicians to determine lesion volumes for a wide variety of different thresholds. The platform includes four different imaging products, tailored to the particular needs of each facility: RAPID MRI provides fully automated, easy-to-interpret diffusion and perfusion maps that identify brain areas with low ADC values, as well as delayed contrast arrival. RAPID MRI perfusion automatically quantifies regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds. RAPID CTP provides perfusion maps that automatically quantify regions of reduced cerebral blood flow, volume and transit time that exceed pre-specified thresholds. Regions are color coded, and the volumes of interest are automatically measured. Maps (including mismatch maps) of the severity of Tmax delays are provided using a four-color-coded scale. RAPID CTA automatically provides clear, easy-to-interpret CTA maps which include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple fourcolor-coded scale. Additionally, a 3D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles. RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. RAPID ASPECTS is CE Marked.
featured-image

Press Release

iSchemaView Completes MDSAP Audit, Moves to Expand Worldwide Adoption of Rapid Imaging Platform

Critical International Audit Paves Way for Regulatory Application and Approvals Around the World. Canadian Representative Launched. Redwood City, Calif. – June 5, 2018 – iSchemaView, the leader in cerebrovascular imaging analysis, today announced that the company has completed the Medical Device Single Audit Program (MDSAP), with coming certification. iSchemaView is now applying for clearances and approvals of the RAPID imaging platform in all participating countries around the world. In 2014, the International Medical Device Regulators Forum (IMDRF) launched a global approach to auditing and monitoring the manufacturing of medical devices, in an effort to improve safety and oversight on an international scale. The result was the creation of the MDSAP, a regulatory audit that serves as a critical step in satisfying the relevant requirements of international regulatory authorities. MDSAP participating countries include Australia, Brazil, Canada, Japan and the United States, with the World Health Organization and European Union among official observers. “With dozens of new stroke centers installing RAPID’s automated CTP, MR, CTA and ASPECTS solutions each month, we are seeing accelerating adoption this year,” said Don Listwin, CEO of iSchemaView. “Now that we have completed the MDSAP we are looking to ensure that patients to our North, and around the world, can take advantage of our unmatched imaging solutions. Our mission is to help health care systems address and treat more stroke patients than ever before, and this news moves us ever more swiftly down the path of success.” With MDSAP complete, iSchemaview will be pursuing approval for RAPID in all participating countries, with estimated clearance in Canada expected this summer. In lock-step with the process, iSchemaview is also announcing that Kevin Talmage of Yocan Medical Systems will partner with the company as a Canadian region representative. Talmage brings with him over twenty years of successful medical device marketing and sales experience across Canada. For more information about working with RAPID in Canada, contact Kevin Talmage at (647) 271- 2516 or at kevin.talmage@yocanmedical.ca .
featured-image

Press Release

iSchemaView Introduces Rapid ASPECTS

State-of-the-Art Imaging Solution Provides Automated Scoring to Assess Early Signs of Brain Ischemia Gothenburg, Sweden – May 15, 2018 – Today at the European Stroke Organization Conference, iSchemaView, the leader in automated cerebrovascular imaging analysis, publicly launched RAPID ASPECTS, a digital imaging solution that assists clinicians in assessing early signs of brain ischemia in stroke. RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. RAPID ASPECTS is CE-marked for use in Europe. The original Alberta Stroke Program Early CT Score (ASPECTS) is a manual 10-point scoring system that relies on determining subtle changes in non-contrast CT examinations. This has traditionally required the expertise of an experienced neuroradiologist or stroke neurologist. Yet even stroke imaging experts have been shown to display significant scoring variability in most studies using ASPECTS. RAPID ASPECTS automates and standardizes the scoring process to help clinicians more accurately assess early signs of brain ischemia. “In my opinion, using RAPID ASPECTS increases the likelihood of getting a reliable ASPECT score, independent of the individual skills and experience of the clinician. This tool is therefore particularly suitable for primary stroke centers with a smaller number of cases,” said Dr. Benjamin Friedrich, docent and physician in the Department of Diagnostic and Interventional Neuroradiology at the Klinikum rechts der Isar in Munich. “Early and reliable information makes it possible to quickly understand the prognosis of a patient.” “ASPECT scoring plays a critical role in the treatment of brain ischemia leading to stroke and is part of the American Heart Association guidelines for use of endovascular therapy in patients who can be treated within six hours of symptom onset,” said Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of iSchemaView. “RAPID ASPECTS elevates the ASPECT scoring system, by providing clinicians with more reliable and reproducible scores and powerful visualization tools to support treatment decisions". RAPID ASPECTS receives data from standard CT scanners, tilt-corrects the images and identifies the ASPECTS regions. A sliding confidence indicator allows the physician to scrutinize suspicious regions and determine a final score. Moving the confidence slider to the left identifies additional regions that may potentially be involved, while moving the slider to the right removes regions with more subtle differences. In addition, RAPID ASPECTS includes these features: Slice up and down, zoom and window options that enable the clinician to evaluate different regions of interest Manual score adjustment by adding or subtracting regions Return to fully automated score with one click “RAPID ASPECTS is the state-of-the-art offering for consistent, actionable ASPECT scoring,” said Don Listwin, CEO of iSchemaView. “Clinicians who use RAPID ASPECTS are better able to facilitate quick diagnoses and share information with internal care teams or specialty treatment centers for referrals. Whether it’s CTP, CTA, MRI or now ASPECTS, more than four hundred stroke centers worldwide are using RAPID imaging solutions to successfully identify and treat more stroke patients than ever before.” Key Presentations at ESOC iSchemaView cofounder, Dr. Greg Albers, will present at three sessions: “Key Subgroup Analyses From the DEFUSE 3 Study” during the Presidential Symposium on Wednesday, May 16 at 15:00 in Hall C. “Validation of the Clinical/Core Mismatch and Perfusion/Core Mismatch Selection Criteria for Late Window Thrombectomy: Pooled Analysis of DEFUSE 3 And DAWN” during the Reperfusion II session on Thursday, May 17 at 10:40 in Hall K3. Medtronic Care Continuum: Patient Pathway , Thursday, May 17, at 12:45 in Hall K1. Dr. Benjamin Friedrich of the Department of diagnostic and interventional Neuroradiology at the Klinikum rechts der Isar will present a paper on automated ASPECTS scoring software, titled “Software-Based, Automated Calculation of the ASPECT Score In Patients Suffering From Emergent Vessel Occlusions in the Anterior Circulation – Clinical Feasibility And Reliability,” during the Reperfusion Trials session on Friday, May 18 at 09:50 in Hall K2.
6 7 8 9